Fog Pharmaceuticals' Series B Round

Fog Pharmaceuticals raised a round of funding on February 14, 2018.

Fog Pharmaceuticals is dedicated to the creation of a new class of medicines that target human disease drivers currently considered "undruggable." The company's cell-penetrating miniproteins (CPMPs) c…

Articles about Fog Pharmaceuticals' Series B Round: